Navigation Links
Breast inflammation is key to cancer growth, Kimmel Cancer Center researchers say
Date:12/14/2010

PHILADELPHIA It took 12 years and a creation of a highly sophisticated transgenic mouse, but researchers at Kimmel Cancer Center at Jefferson have finally proven a long suspected theory: Inflammation in the breast is key to the development and progression of breast cancer.

In the December 15 issue of Cancer Research, the scientists say they can now definitively show that an inflammatory process within the breast itself promotes growth of breast cancer stem cells responsible for tumor development.

They also demonstrate that inactivating this inflammation selectively within the breast reduced activity of these stem cells, and stopped breast cancer from forming.

"These studies show for the first time that inactivating the NFKB inflammatory pathway in the breast epithelium blocks the onset and progression of breast cancer in living animals," says Richard G. Pestell, M.D., Ph.D., Director, Kimmel Cancer Center and Chairman of Cancer Biology.

"This finding has clinical implications," says co-author Michael Lisanti, Leader of the Program in Molecular Biology and Genetics of Cancer at Jefferson. "Suppressing the whole body's inflammatory process has side effects. These studies provide the rationale for more selective anti-inflammatory therapy directed just to the breast."

Dr. Pestell and his colleagues show the "canonical" NFKB pathway promotes breast cancer development: the first "insult" is provided by the HER2 oncogene, which then activates NFKB (nuclear factor kappa-light-chain-enhancer of activated B cells). NFKB turns on inflammation via tumor-associated macrophages (TAM), which produce tumor growth promoting factors.

Although inflammation, mediated by NFKB, has long been thought to be important in breast cancer development, the theory had been untestable because NF-κB is essential to embryonic development, Dr. Pestell says. "When you try to knock out NFKB genes in mice, they die."

He addressed this problem by creating a mouse in which the inflammatory system within the adult animal's normal breast could be regulated. This allows selective inactivation of NFKB in different cell types and took 12 years to accomplish, Dr. Pestell says. "These mice have five co-integrated transgenes."

The mice are programmed to develop breast cancer, but the researchers found that if they selectively blocked inflammation just in the breast, tumors would not develop. "This is a very novel finding," Dr. Pestell says.

They then demonstrated that this inactivation also reduced the number of cancer stem cells in the breast. "That told us that inflammation, through the action of NF-κB, is important to the growth and activity of cancer stem cells," Dr. Pestell says. "The transgenic mice are a new technology that can be used by the scientists and the pharmaceutical industry to understand the role of NFKB in different diseases including heart disease, neurodegeneration and other cancers."


'/>"/>

Contact: Ed Federico
ed.federico@hotmail.com
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Certain Drug Combinations May Beat Back Aggressive Breast Cancer
2. Stray Breast Tumor Cells in Early Chemo Could Be Bad Sign
3. Higher co-payments increase chance of early discontinuation of breast cancer therapy
4. Depression drug may relieve pain from breast cancer treatment, U-M study finds
5. Novel imaging technique may reduce lymphedema in breast cancer patients
6. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
7. Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer
8. High CTC levels predicted poor outcome in metastatic breast cancer
9. CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer
10. Poor breast cancer prognosis associated with presence of circulating tumor, cancer stem cells
11. Trio of drugs may combat triple negative breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... , ... Just ask anyone old enough to remember what it was like ... up and containing so much metal that jokes about radio reception abounded. But thanks ... barely be observed. As a result, it’s now a billion-dollar industry and is, in ...
(Date:9/25/2017)... ... September 25, 2017 , ... Tim Rial Agency of Burleson, TX announces the ... By working closely with nonprofit groups and community leaders, the agency hopes to bring ... worthy organizations, families and individuals. , Tim Rial, the owner of Tim Rial ...
(Date:9/25/2017)... ... September 25, 2017 , ... NCPDP Foundation ... that it has awarded a $40,000 grant to Johns Hopkins Medicine to address ... CancelRx enables prescribers to electronically cancel a prescription already submitted to a pharmacy. ...
(Date:9/25/2017)... ... September 25, 2017 , ... Bobbie Horowitz was hardly able ... multiple health issues. As a cabaret and theater producer, Horowitz would manage to get ... of transportation in New York City, so she had to take a cab everywhere. ...
(Date:9/25/2017)... Port Richey, FL (PRWEB) , ... September 25, 2017 , ... ... New Port Richey, Fla. location at 5304 Main Street as an interventional pain management ... of the spine and extremities. He joins PPOA from private practice In Brooksville, Fla. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
Breaking Medicine Technology: